Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
- 992 Downloads
Enzalutamide (MDV3100, XTANDI®) is an androgen receptor inhibitor that is indicated for the treatment of metastatic, castration-resistant, prostate cancer (mCRPC) that has progressed despite treatment with docetaxel. This article reviews the pharmacology, efficacy and tolerability of enzalutamide relevant to this indication. In a randomized, double-blind, placebo-controlled, multinational, phase III trial in patients with mCRPC progressing after docetaxel therapy, enzalutamide significantly prolonged overall survival (OS), delayed prostate specific antigen progression and prolonged radiographic progression-free survival and time to the first skeletal event. The median OS was 18.4 months in the enzalutamide group and 13.6 months in the placebo group, which represents a 37 % reduction in the mortality risk in the enzalutamide group. Enzalutamide was also associated with significant benefits in health-related quality of life and in pain palliation. Enzalutamide was generally as well tolerated as placebo during the trial, with most adverse events at a mild or moderate level of severity. Enzalutamide carries a small increased risk of seizures that appears to be dose-dependent. Enzalutamide is an efficacious and well tolerated treatment for this severe, rapidly progressive disease.
KeywordsOverall Survival Docetaxel Androgen Deprivation Therapy Abiraterone Enzalutamide
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
- 5.Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. 2013. https://www.auanet.org/common/pdf/education/clinical-guidance/Castration-Resistant-Prostate-Cancer.pdf. Accessed 23 Sept 2013.
- 14.National Cancer Institute, National Institutes of Health. FDA approval for radium 223 dichloride. 2013. http://cancer.gov/cancertopics/druginfo/fda-radium-223-dichloride. Accessed 4 Sept 2013.
- 15.Astellas Pharma US, Inc. XTANDI® (enzalutamide) capsules for oral use: US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf. Accessed 23 Sept 2013.
- 16.European Medicines Agency. Xtandi 40 mg soft capsules: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002639.pdf. Accessed 28 Aug 2013.
- 17.Astellas Pharma. XTANDI® (Enzalutamide) capsules receives Health Canada approval for treatment of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel [media release] 4 June 2013. http://www.astellas.com.
- 23.Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013; 2:e00499.Google Scholar
- 28.Fleming MT, Rathkopf DE, Gibbons J, et al. Enzalutamide (ENZA) in combination with docetaxel in men with prostate cancer: preliminary results from a phase I study [abstract no. 63]. J Clin Oncol. 2013; 31(6 Suppl 1).Google Scholar
- 31.de Bono J, Fizazi K, Shore N, et al. Assessing the impact of prior treatments on the efficacy of enzalutamide (ENZ): a subanalysis of the phase 3 AFFIRM trial (abstract). 38th European Society for Medical Oncology Annual Meeting; 27 September–1 October 2013, Amsterdam.Google Scholar
- 32.Scher H, Fizazi K, Saad F, et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor [abstract no. 6]. J Clin Ocol. 2013;31(6 Suppl 1).Google Scholar
- 33.Sternberg CN, De Bono JS, Chi KN, et al. Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial [abstract no. 16]. J Clin Oncol. 2013;31(6 Suppl 1).Google Scholar
- 34.Saad F, De Bono JS, Shore ND, et al. Efficacy outcomes by baseline prostate-specific antigen (PSA): results from the phase 3 AFFIRM trial [abstract no. 785]. 108th Annual Meeting of the American Urological Association; 2013; San Diego, CA.Google Scholar
- 35.Loriot Y, Fizazi K, De Bono J, et al. Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial [abstract no. 5065]. J Clin Oncol. 2013;31(15 Suppl 1).Google Scholar
- 36.Miller K, Scher HI, Fizazi K, et al. Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) [abstract no. 17]. J Clin Oncol. 2013;31(6 Suppl 1).Google Scholar
- 37.Fizazi K, Scher HI, Saad F, et al. Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (Sre) and pain in the phase 3 Affirm study [abstract no. 8960]. 37th Congress of the European Society for Medical Oncology, 2012, Vienna.Google Scholar
- 38.Data on file, Astellas Pharma, 2013.Google Scholar
- 39.Tombal B, Borre M, Rathenborg P, et al. Enzalutamide monotherapy: phase II study results in patients with hormone-naive prostate cancer [abstract no. 18]. J Clin Oncol. 2013;31(6 Suppl 1).Google Scholar
- 40.Medivation, Inc. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). 2013. http://clinicaltrials.gov/show/NCT01212991. Accessed 23 Sept 2013.